دورية أكاديمية
أعرض في EDS

Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.

التفاصيل البيبلوغرافية
العنوان: Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.
المؤلفون: Sidorenko V; Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, 50411, Tartu, Estonia., Scodeller P; Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain., Uustare A; ToxInvent LLC, Tiigi 61b, 50410, Tartu, Estonia., Ogibalov I; ToxInvent LLC, Tiigi 61b, 50410, Tartu, Estonia., Tasa A; ToxInvent LLC, Tiigi 61b, 50410, Tartu, Estonia., Tshubrik O; ToxInvent LLC, Tiigi 61b, 50410, Tartu, Estonia., Salumäe L; Department, of Pathology, Tartu University Hospital, 50410, Tartu, Estonia., Sugahara KN; Division of GI/Endocrine Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, 10032, USA., Simón-Gracia L; Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, 50411, Tartu, Estonia. Lorena.Simon.Gracia@ut.ee., Teesalu T; Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, 50411, Tartu, Estonia. Tambet.Teesalu@ut.ee.; Materials Research Laboratory, University of California, Santa Barbara, CA, 93106, USA. Tambet.Teesalu@ut.ee.
المصدر: Scientific reports [Sci Rep] 2024 Jul 30; Vol. 14 (1), pp. 17513. Date of Electronic Publication: 2024 Jul 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Tumor Microenvironment*/drug effects , Nanoparticles*/chemistry, Animals ; Mice ; Female ; Bibenzyls/pharmacology ; Bibenzyls/chemistry ; Cell Line, Tumor ; Humans ; Stilbenes/pharmacology ; Stilbenes/administration & dosage ; Oligopeptides/chemistry ; Oligopeptides/pharmacology ; Neuropilin-1/metabolism ; Peritoneal Neoplasms/drug therapy ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Breast Neoplasms/metabolism ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/administration & dosage
مستخلص: Cancer treatment with vascular disrupting agents (VDAs) causes rapid and extensive necrosis in solid tumors. However, these agents fall short in eliminating all malignant cells, ultimately leading to tumor regrowth. Here, we investigated whether the molecular changes in the tumor microenvironment induced by VDA treatment sensitize the tumors for secondary nanotherapy enhanced by clinical-stage tumor penetrating peptide iRGD. Treatment of peritoneal carcinomatosis (PC) and breast cancer mice with VDA combretastatin A-4 phosphate (CA4P) resulted in upregulation of the iRGD receptors αv-integrins and NRP-1, particularly in the peripheral tumor tissue. In PC mice treated with CA4P, coadministration of iRGD resulted in an approximately threefold increase in tumor accumulation and a more homogenous distribution of intraperitoneally administered nanoparticles. Notably, treatment with a combination of CA4P, iRGD, and polymersomes loaded with a novel anthracycline Utorubicin (UTO-PS) resulted in a significant decrease in the overall tumor burden in PC-bearing mice, while avoiding overt toxicities. Our results indicate that VDA-treated tumors can be targeted therapeutically using iRGD-potentiated nanotherapy and warrant further studies on the sequential targeting of VDA-induced molecular signatures.
(© 2024. The Author(s).)
References: J Control Release. 2006 Aug 28;114(2):230-41. (PMID: 16876899)
Sci Signal. 2016 Apr 26;9(425):ra42. (PMID: 27117252)
Lancet Gastroenterol Hepatol. 2022 Oct;7(10):943-951. (PMID: 35803294)
Oncotarget. 2016 Mar 29;7(13):15444-59. (PMID: 26812886)
Chembiochem. 2016 Apr 1;17(7):570-5. (PMID: 26895508)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 May;9(3):. (PMID: 28185434)
Annu Rev Cell Dev Biol. 1996;12:697-715. (PMID: 8970741)
Cancer Treat Rev. 2001 Dec;27(6):365-74. (PMID: 11908929)
Clin Pharmacol Ther. 2012 Sep;92(3):332-9. (PMID: 22871997)
Mol Ther. 2020 Jan 8;28(1):75-88. (PMID: 31672285)
Anticancer Res. 2008 Jul-Aug;28(4B):2027-31. (PMID: 18751370)
Kurume Med J. 2011;58(3):73-9. (PMID: 22531121)
Science. 2010 May 21;328(5981):1031-5. (PMID: 20378772)
J Clin Med. 2022 Mar 07;11(5):. (PMID: 35268546)
Sci Am. 1994 Jul;271(1):58-65. (PMID: 8066425)
Nat Rev Cancer. 2005 Jun;5(6):423-35. (PMID: 15928673)
Cancer Res. 2001 Sep 15;61(18):6811-5. (PMID: 11559555)
J Clin Invest. 2016 Oct 3;126(10):3672-3679. (PMID: 27482883)
J Clin Oncol. 2003 Dec 1;21(23):4428-38. (PMID: 14645433)
Adv Protein Chem Struct Biol. 2015;98:1-55. (PMID: 25819275)
Science. 2016 Apr 8;352(6282):175-80. (PMID: 27124451)
J Clin Invest. 2005 Nov;115(11):2992-3006. (PMID: 16224539)
Lancet Oncol. 2017 Aug;18(8):e445-e456. (PMID: 28759384)
Nano Today. 2014 Oct;9(5):550-559. (PMID: 29731806)
Gynecol Oncol Res Pract. 2018 Jan 5;5:1. (PMID: 29318022)
World J Gastroenterol. 2013 Nov 7;19(41):6979-94. (PMID: 24222942)
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7. (PMID: 17448875)
Cancer Med. 2013 Oct;2(5):595-610. (PMID: 24403226)
Mol Pharm. 2020 Jul 6;17(7):2518-2531. (PMID: 32421341)
J Control Release. 2017 Aug 28;260:46-60. (PMID: 28536049)
Proc Natl Acad Sci U S A. 2021 Nov 16;118(49):. (PMID: 34772761)
Cancer Res. 2002 Jun 15;62(12):3408-16. (PMID: 12067983)
Angew Chem Int Ed Engl. 2021 Jul 26;60(31):17018-17027. (PMID: 33908690)
Anticancer Res. 1999 Jan-Feb;19(1A):189-95. (PMID: 10226542)
Molecules. 2018 May 16;23(5):. (PMID: 29772690)
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20. (PMID: 15701823)
Bioconjug Chem. 2011 Jul 20;22(7):1270-8. (PMID: 21639139)
Sci Rep. 2020 Apr 2;10(1):5809. (PMID: 32242067)
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1491-6. (PMID: 12459376)
Br J Cancer. 2004 Feb 9;90(3):705-11. (PMID: 14760388)
Clin Adv Hematol Oncol. 2022 Nov;20(11):673-682. (PMID: 36331405)
Br J Cancer. 1999 Dec;81(8):1318-27. (PMID: 10604728)
Molecules. 2020 Feb 13;25(4):. (PMID: 32069856)
Cancer Sci. 2021 Aug;112(8):2966-2974. (PMID: 33966313)
Cell Death Dis. 2021 Apr 13;12(4):394. (PMID: 33850110)
Cells. 2019 Dec 10;8(12):. (PMID: 31835465)
J Clin Oncol. 2003 Aug 1;21(15):2815-22. (PMID: 12807934)
Br J Radiol. 2008 Oct;81 Spec No 1:S12-20. (PMID: 18819993)
J Natl Cancer Inst. 2001 Feb 21;93(4):309-14. (PMID: 11181778)
ACS Nano. 2019 Oct 22;13(10):11008-11021. (PMID: 31503443)
Adv Drug Deliv Rev. 2017 Jan 1;108:13-24. (PMID: 27422808)
Sci Rep. 2014 Jun 10;4:5232. (PMID: 24912981)
Int J Hyperthermia. 2017 Aug;33(5):534-542. (PMID: 28540828)
Mol Cancer Ther. 2016 Apr;15(4):670-9. (PMID: 26880267)
BMC Cancer. 2006 Dec 07;6:280. (PMID: 17156434)
Cancers (Basel). 2021 Apr 04;13(7):. (PMID: 33916607)
Int J Mol Sci. 2020 Jul 06;21(13):. (PMID: 32640548)
Cancer. 2004 Jun 15;100(12):2491-9. (PMID: 15197790)
J Control Release. 2015 Aug 28;212:59-69. (PMID: 26071630)
Chem Rev. 2016 Feb 10;116(3):1053-93. (PMID: 26322859)
Cancers (Basel). 2022 May 30;14(11):. (PMID: 35681691)
Biomaterials. 2019 Oct;219:119373. (PMID: 31374479)
J Control Release. 2017 Dec 28;268:49-56. (PMID: 29030222)
Drug Resist Updat. 2005 Dec;8(6):381-402. (PMID: 16309948)
Annu Rev Pathol. 2014;9:47-71. (PMID: 23937437)
Cancer Treat Rev. 2011 Feb;37(1):63-74. (PMID: 20570444)
Oncotarget. 2018 Apr 10;9(27):18682-18697. (PMID: 29721153)
Circ Res. 2005 Jun 24;96(12):1257-65. (PMID: 15920019)
Int J Oncol. 2013 Nov;43(5):1431-40. (PMID: 23970191)
Neoplasia. 2004 Mar-Apr;6(2):117-27. (PMID: 15140400)
Int J Clin Oncol. 2007 Feb;12(1):17-24. (PMID: 17380436)
J Am Chem Soc. 2013 Apr 24;135(16):5966-9. (PMID: 23565759)
Cancer Cell. 2009 Dec 8;16(6):510-20. (PMID: 19962669)
Nat Med. 2002 Jul;8(7):751-5. (PMID: 12053175)
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62. (PMID: 19805273)
Mol Biol Cell. 2005 Apr;16(4):1901-12. (PMID: 15689487)
Nat Commun. 2014 Oct 03;5:4904. (PMID: 25277522)
Cancer Res. 1997 May 15;57(10):1829-34. (PMID: 9157969)
Eur J Pharmacol. 2021 Jan 15;891:173692. (PMID: 33130277)
Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75. (PMID: 28185035)
Expert Rev Clin Pharmacol. 2022 Jan;15(1):43-49. (PMID: 35184625)
Cancer Res. 2006 Dec 15;66(24):11520-39. (PMID: 17178843)
Biomaterials. 2016 Oct;104:247-57. (PMID: 27472162)
معلومات مُعتمدة: RYC2020-028754-I Ministerio de Ciencia e Innovación; LMVBS17506 Sihtasutus Archimedes; LMVBS17506 Sihtasutus Archimedes; LMVBS17506 Sihtasutus Archimedes; MOBJD11 European Regional Development Fund; 2014-2020.4.01.15-0012 European Regional Development Fund; PRG230 Eesti Teadusagentuur; ECM-CART EuroNanoMed III; ReachGLIO TRANSCAN3
فهرسة مساهمة: Keywords: CA4P; Peritoneal carcinomatosis; Polymersomes; Tumor-penetrating peptide; Utorubicin; Vascular disrupting agent; iRGD
المشرفين على المادة: 0 (Bibenzyls)
0 (Stilbenes)
I5590ES2QZ (fosbretabulin)
0 (Oligopeptides)
144713-63-3 (Neuropilin-1)
0 (N-end cysteine peptide tumor-homing peptide)
0 (Antineoplastic Agents)
تواريخ الأحداث: Date Created: 20240730 Date Completed: 20240731 Latest Revision: 20240807
رمز التحديث: 20240807
مُعرف محوري في PubMed: PMC11289491
DOI: 10.1038/s41598-024-64610-7
PMID: 39080306
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-64610-7